Hemodynamic Change of Coronary Atherosclerotic Plaque After Evolocumab Treatment

Inclusion Criteria: * 1.baseline CCTA revealed at least one lesion with stenotic extent from 50% to 69% on major epicardial arteries (diameter ≧2 mm); * 2.patients were referred for optimal medical treatment; * 3.patients agreed to undergo follow-up CCTA at 1-year interval. Exclusion Criteria: * 1.patients had previous history of myocardial infarction or coronary revascularization; * 2.patients were contraindicated to the usage of iodine contrast media; * 3.image quality of baseline or follow-up CCTA was severely impaired (in presence of severe artifact, non-diagnostic); * 4.patients withdrew the informed consents during follow-up; * 5.patients experienced major adverse cardiac events during follow-up; * 6.patients refused to undergo follow-up CCTA; * 7.lost follow-up